Pregabalin Capsule
Product Images NDC 50228-350

Product Visual Gallery

This gallery contains 37 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50228-350). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (100 mg Capsule Blister Pack)

Label for Pregabalin Capsules 100 mg by ScieGen Pharmaceuticals, Inc. The label indicates that the container holds 1,000 oral capsules. Storage instructions specify 25°C (77°F) with permitted excursions to 15 to 30°C (59 to 86°F). The label notes that each capsule contains 100 mg pregabalin and advises dispensing in child-resistant containers with the accompanying Medication Guide.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

Label for Pregabalin Capsules 100 mg by ScieGen Pharmaceuticals, Inc. The label indicates storage instructions, dosage information pointing to accompanying prescribing info, and that each capsule contains 100 mg pregabalin. The package contains 30 capsules and is labeled for prescription use only. Manufacturer information and an NDC barcode are also present.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle)

Pregabalin Capsules 100 mg oral dosage form packaging label by ScieGen Pharmaceuticals, Inc. The label includes the NDC 50228-353-90 and states a package quantity of 90 capsules. It instructs to dispense the accompanying medication guide and store at 25°C with permitted excursions. The label also specifies the product is Rx Only and packaged in child-resistant containers.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle Label)

Label for Pregabalin Capsules 150 mg by ScieGen Pharmaceuticals, Inc. The label includes storage instructions, dosage caution, and highlights that each capsule contains 150 mg pregabalin. It indicates the package contains 1,000 capsules and is for prescription use only. There is a barcode and manufacturing details on the right side.*

FDA Label Image

Principal Display Panel (150 mg Capsule Blister Pack Carton)

Label for Pregabalin Capsules 150 mg by ScieGen Pharmaceuticals, Inc. The label states storage instructions, dosage referencing accompanying prescribing information, and that each capsule contains 150 mg pregabalin. The package contains 30 capsules, marked Rx only, with a barcode and manufacturer details from Hauppauge, NY.*

FDA Label Image

Principal Display Panel (150 mg Capsule Blister Pack Carton)

Label for Pregabalin Capsules 150 mg by ScieGen Pharmaceuticals, Inc. The label includes dosage information, storage instructions (store at 25°C with permitted excursions to 15-30°C), and dispensing guidelines (tight, child-resistant containers). The package contains 90 capsules and is for prescription use only. The label features the product NDC 50228-354-90 and a barcode.*

FDA Label Image

Principal Display Panel (200 mg Capsule Blister Pack)

Label for Pregabalin Capsules 200 mg by ScieGen Pharmaceuticals, Inc. The label specifies storage instructions, dosage form as capsules, quantity of 30 capsules per container, and includes a barcode and NDC number 50228-355-30. It also indicates prescription use only and advises dispensing the Medication Guide to patients.*

FDA Label Image

Principal Display Panel (200 mg Capsule Blister Pack Carton)

Pregabalin Capsules 200 mg oral capsule label by ScieGen Pharmaceuticals, Inc. The label indicates a bottle size of 500 capsules with Rx only status. Storage instructions specify 25°C (77°F) with permitted excursions, and dispensing in child-resistant containers. The label includes a barcode and directs users to accompanying prescribing information.*

FDA Label Image

Principal Display Panel (200 mg Capsule Blister Pack)

Pregabalin Capsules 200 mg oral dosage form packaging label from ScieGen Pharmaceuticals, Inc. The label states the product contains 90 capsules and is prescription only. It includes storage instructions, dosage guidance to see accompanying prescribing information, and a barcode. Manufactured by ScieGen Pharmaceuticals, Hauppauge, NY.*

FDA Label Image

Principal Display Panel (225 mg Capsule Bottle Label)

Label for Pregabalin Capsules 225 mg, oral dosage form by ScieGen Pharmaceuticals, Inc. The label includes storage instructions, dosage note, and package size of 30 capsules. It displays the NDC code 50228-356-30 and specifies that the product is prescription only (Rx only).*

FDA Label Image

Principal Display Panel (225 mg Capsule Bottle Label)

Label for Pregabalin Capsules 225 mg by ScieGen Pharmaceuticals, Inc. The label includes storage instructions, dispensing guidance, and dosage information. It states the package contains 500 capsules and is prescription only. The label also shows the NDC code 50228-356-05 and a barcode.*

FDA Label Image

Principal Display Panel (225 mg Capsule Bottle Label)

Pregabalin Capsules 225 mg label from ScieGen Pharmaceuticals, Inc. The label indicates the capsule strength as 225 mg of pregabalin. It includes storage instructions at 25°C with permitted excursions, dispensing information for child-resistant containers, and directs to accompanying prescribing information. The package contains 90 capsules and is marked Rx Only. A barcode and the NDC number 50228-356-90 are present.*

FDA Label Image

Principal Display Panel (25 mg Capsule Blister Pack)

Label for Pregabalin Capsules 25 mg by ScieGen Pharmaceuticals, Inc. The label indicates 1,000 capsules in the container, with prescription only status. Storage instructions specify 25°C (77°F) with permitted excursions, and capsules are to be dispensed in child-resistant containers. The label includes NDC 50228-350-10 and space for lot and expiration dates.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

Label for Pregabalin Capsules 25 mg by ScieGen Pharmaceuticals, Inc. The label states storage instructions, dosage, and usage notes, and specifies 30 capsules with a prescription-only designation. It includes a barcode and manufacturer address in Hauppauge, NY.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle)

Pregabalin Capsules 25 mg oral capsules label from ScieGen Pharmaceuticals, Inc. The label states each capsule contains 25 mg pregabalin, and the package contains 90 capsules. Storage instructions indicate 25°C (77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). It notes dispensing in child-resistant containers and includes a barcode and NDC 50228-350-90.*

FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

Pregabalin 300 mg Capsules label from ScieGen Pharmaceuticals, Inc. The label shows a 30-capsule package of oral prescription capsules containing 300 mg of pregabalin each. Storage instructions, dosage guidance, and barcode are visible, along with the manufacturer information located in Hauppauge, NY.*

FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

Pregabalin Capsules 300 mg oral dosage form label by ScieGen Pharmaceuticals, Inc. The label states the product contains 300 mg pregabalin per capsule, with a quantity of 500 capsules. Storage instructions specify 25°C (77°F) with permitted excursions, and it requires dispensing in child-resistant containers. Includes a barcode and mentions accompanying prescribing information and medication guide.*

FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

Pregabalin Capsules 300 mg oral capsules label from ScieGen Pharmaceuticals, Inc. The label includes dosage and use instructions, storage conditions, and the package contains 90 capsules. It instructs to dispense with accompanying medication guide and specifies that the capsules are prescription only (Rx Only). The NDC code 50228-357-90 is displayed with a barcode.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Label for Pregabalin Capsules 50 mg by ScieGen Pharmaceuticals, Inc. The label states the product contains 50 mg pregabalin per capsule, with a bottle count of 1,000 capsules. Storage instructions specify 25°C with excursions permitted between 15 to 30°C. The label includes directions to dispense in child-resistant containers and to provide the accompanying Medication Guide to patients.*

FDA Label Image

Principal Display Panel (50 mg Capsule Blister Pack Carton)

Label for Pregabalin Capsules 50 mg manufactured by ScieGen Pharmaceuticals, Inc. The label includes storage instructions, dosage note, and specifies 30 capsules per bottle. It features the National Drug Code (NDC) 50228-351-30 and indicates the product is prescription only with child-resistant packaging.*

FDA Label Image

Principal Display Panel (50 mg Capsule Blister Pack)

Pregabalin Capsules 50 mg oral dosage form label by ScieGen Pharmaceuticals, Inc. The label states each capsule contains 50 mg pregabalin and instructs to dispense the accompanying Medication Guide. The package contains 90 capsules and is marked Rx Only, with storage instructions and manufacturer information included.*

FDA Label Image

Principal Display Panel (75 mg Capsule Blister Pack Carton)

Label for Pregabalin Capsules 75 mg by ScieGen Pharmaceuticals, Inc., containing 1,000 capsules. The label includes storage instructions to keep at 25°C (77°F) with permitted excursions, child-resistant container advice, and a note to see accompanying prescribing information. The NDC code 50228-352-10 and barcode are visible.*

FDA Label Image

Principal Display Panel (75 mg Capsule Blister Pack)

Label for Pregabalin Capsules 75 mg oral capsules by ScieGen Pharmaceuticals, Inc. The label includes storage instructions, a note to dispense in child-resistant containers, dosage referencing accompanying prescribing info, and states each capsule contains 75 mg pregabalin. The package contains 30 capsules and is marked Rx only.*

FDA Label Image

Principal Display Panel (75 mg Capsule Blister Pack)

Pregabalin Capsules 75 mg oral dosage form label from ScieGen Pharmaceuticals, Inc. The label states each capsule contains 75 mg pregabalin and comes in a 90-capsule container. It includes storage instructions, a barcode, NDC 50228-352-90, and directions to dispense accompanying medication guides. Manufactured by ScieGen Pharmaceuticals, Inc., Hauppauge, NY.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses 25 mg, 100 mg, and 200 mg taken three times a day, compared to placebo. Each dosage is represented by a distinct line, illustrating differences in patient response rates across varying pain improvement percentages.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day compared to placebo. The graph shows higher patient improvement percentages with Pregabalin across various levels of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting the percent of patients improved versus the percent improvement in pain from baseline. It compares Pregabalin at dosages of 300 mg, 150 mg, and 75 mg taken two times a day against a placebo group, showing the relative improvement in pain among different treatment groups.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline. It shows three lines representing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating patient response rates across varying pain improvement percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 50 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows percent improvement on the x-axis and percent of patients improved on the y-axis, with three lines comparing the treatments.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) in two clinical studies (Study E1 and Study E3) for Pregabalin at various dosages versus placebo. The vertical axis shows responder rate percentage, while the horizontal axis lists dosages and placebo groups with subject counts. Statistically significant increases versus placebo are marked.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percent change from baseline against dose in mg/day for pregabalin. It includes data series labeled Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID, with plotted points and associated p-values denoting statistical significance.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin daily doses of 300 mg, 450 mg, and 800 mg with a placebo group. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis represents percent of patients improved (0 to 100%). Different line styles distinguish the dose groups and placebo.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve comparing Pregabalin and Placebo over 180 days, showing the estimated percentage of subjects without LTR (loss to response). The graph has days on the x-axis and estimated percent subjects without LTR on the y-axis. Pregabalin shows a higher percentage over time compared to Placebo.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over different percentages improved from baseline to Week 12 BOCF for Pregabalin versus Placebo. The solid line represents Pregabalin showing higher improvement percentages, and the dashed line represents Placebo with lower improvement. The x-axis indicates percent improved from baseline to Week 12, and the y-axis shows the percent of subjects improved.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved from baseline to Week 16 BOCF between Pregabalin and placebo groups. The x-axis shows percent improvement ranging from 0 to 100, while the y-axis shows the percent of subjects improved, with Pregabalin depicted by a solid line consistently above the placebo's dotted line.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for calculating creatinine clearance (CLcr) based on patient age, weight, and serum creatinine levels, with an adjustment factor for female patients. The formula is shown as an equation using age in years, weight in kilograms, and serum creatinine in mg/dL.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, showing the molecular arrangement of atoms including amino and carboxyl functional groups. The image depicts bonds and stereochemistry relevant to the active ingredient pregabalin in the drug product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.